



## Health

Public Health and Primary Health Care Division  
Communicable Disease Control  
4<sup>th</sup> Floor, 300 Carlton St, Winnipeg, MB R3B 3M9  
T 204 788-6737 F 204 948-2040  
[www.manitoba.ca](http://www.manitoba.ca)

February 18, 2014

Dear Health Care Provider:

### Manitoba Health's HPV Immunization Program:

Effective March 31<sup>st</sup> 2014, all Manitoba girls and women in Grade 6 to age 17 (i.e. those born on or after January 1<sup>st</sup> 1997) are eligible to receive the publicly-funded (i.e. free-of-charge) HPV vaccine series. Girls or women with increased risk of HPV infection who started the 3-dose vaccine series before March 31<sup>st</sup> will be eligible to finish the series free-of-charge.

### Manitoba Health's Pneumococcal Conjugate 13 (Pneu-C-13) Immunization Program:

Manitoba Health has updated provincial eligibility criteria for its routine childhood Pneu-C-13 immunization program:

- Children 2 months to < 59 months of age are eligible to receive 3 doses (2, 4 and 12 months of age)\*
- Children 2 months to < 59 months of age living in First Nations communities are eligible to receive 4 doses (2, 4, 6 and 18 months of age)\*
- Children up to 59 months of age who received the 7 valent pneumococcal vaccine (Pneu-C-7) series are eligible to receive 1 dose of Pneu-C-13
- Children 2 months to < 59 months of age with at least one of the following high risk medical conditions are eligible to receive 4 doses (2, 4, 6 and 18 months of age):\*
  - Chronic cerebral spinal fluid (CSF) leak
  - Chronic neurologic condition that may impair clearance of oral secretions
  - Cochlear implants (including those children who are to receive implants)
  - Chronic cardiac or pulmonary disease
  - Diabetes mellitus
  - Asplenia (functional or anatomic)
  - Sickle cell disease or other hemoglobinopathies
  - Congenital immunodeficiencies involving any part of the immune system, including B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions
  - Hematopoietic stem cell transplant (recipient)
  - HIV infection
  - Immunosuppressive therapy including use of long term corticosteroids, chemotherapy, radiation therapy, post-organ transplant therapy, and certain anti-rheumatic drugs
  - Chronic kidney disease, including nephrotic syndrome
  - Chronic liver disease (including hepatic cirrhosis due to any cause)
  - Malignant neoplasms including leukemia and lymphoma
  - Solid organ or islet transplant (candidate or recipient)

\* For late or incomplete dosing schedules, please see the Canadian Immunization Guide

For more information about Manitoba Health's Publicly-Funded Immunization Program including provincial program standards, eligibility criteria and printable immunization schedules, access the province's online *Immunization Program Manual for Immunization Providers in Manitoba* at: [www.gov.mb.ca/health/publichealth/cdc/div/manual/index.html](http://www.gov.mb.ca/health/publichealth/cdc/div/manual/index.html).

Manitoba Health's *Vaccines and Biologics Order Form* is available online at: [www.gov.mb.ca/health/publichealth/cdc/protocol/vaccinebiologics.pdf](http://www.gov.mb.ca/health/publichealth/cdc/protocol/vaccinebiologics.pdf)

Please share this information with all relevant colleagues in your facility or clinic.

Sincerely,

*"Original Signed By"*

Richard Baydack, PhD  
A/Director, Communicable Disease Control

*"Original Signed By"*

Tim Hilderan, MD FRCP, C  
Medical Lead, Communicable Disease Control